Imbruvica plus chemotherapy misses in Phase III for subtype of DLBCL

AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) said Imbruvica ibrutinib plus R-CHOP chemotherapy missed the primary endpoint of improving event-free survival vs. placebo plus R-CHOP chemotherapy in the Phase III PHOENIX trial to treat patients with newly diagnosed non-germinal center B cell subtype of diffuse large B cell lymphoma (DLBCL). J&J plans to conduct additional analyses, including subgroup analyses, ahead of discussions with regulatory authorities.

The double-blind, international trial enrolled 838 patients to receive placebo or once-daily 560 mg Imbruvica plus R-CHOP chemotherapy. Data will be presented at a medical meeting this year...